Why the study?
Do blood-brain barrier-crossing ACE inhibitors reduce the incidence of Alzheimer's disease in elderly hypertensive patients compared to non-crossing ACE inhibitors or other antihypertensives?
Do blood-brain barrier-crossing ACE inhibitors reduce the incidence of Alzheimer's disease in elderly hypertensive patients compared to non-crossing ACE inhibitors or other antihypertensives?
Long-term use of blood-brain barrier-crossing ACE inhibitors may protect against the development of Alzheimer's disease in elderly hypertensive patients, suggesting a potential benefit of specific tissue distribution properties.
Answers are grounded in this paper and cite their sources.
Suggests a potential neuroprotective advantage for BBB-crossing ACE inhibitors in hypertensive patients; leaves open.
To the Editor: According to the Japanese Health and Welfare Ministry, the incidence rate of dementia in Japanese aged 65 and older was 6.3%. The potential reduction of the incidence of dementia using antihypertensive drug treatment1 may have important public-health implications in view of the increasing longevity of populations worldwide. One possible mechanism for this effect might be an improvement in microvascular pathology of the brain by antihypertensive drugs,1,2 but others remain unknown. There is some evidence that certain components of the renin-angiotensin system (RAS) may have a crucial role in learning and memory processes.3,4 Previous studies have reported elevated levels of angiotensin-converting enzyme (ACE) in the hippocampus, parahippocampal gyrus, frontal cortex, and caudate nucleus of patients with Alzheimer's disease (AD), the most common form of dementia.3,4 The increased ACE activity may be directly responsible for cognitive impairment in AD because the enhanced formation of angiotensin II would result in an increased inhibitory effect of angiotensin II on acetylcholine release.3 Marked differences were observed between certain ACE inhibitors with respect to penetration into the brain, where they could directly affect the activity of RAS.5 In the present study, we attempted to test the hypothesis that some ACE inhibitors, which can cross the blood-brain barrier (BBB) and significantly inhibit the brain ACE,5 may have a protective role against the development of AD. Therefore, we investigated the incidence of AD from January 1993 to March 2003 in elderly hypertensive patients treated continuously with ACE inhibitors or other antihypertensive drugs based upon computerized information on patients in our university hospital. Eligible patients had no previous history of dementia; were aged 65 and older; had a stable systolic blood pressure of less than 150 mmHg and diastolic blood pressure of 90 mmHg or less; and were receiving BBB-crossing ACE inhibitors (captopril 37.5 mg/d or perindopril 2 mg/d),5 BBB-noncrossing ACE inhibitors (imidapril 5 mg/d or enalapril 5 mg/d), calcium-channel blockers (nifedipine 20 mg/d or nilvadipine 4 mg/d), beta-blockers (atenolol 50 mg/d or metoprolol 60 mg/d), or diuretics (trichlormethiazide 2 mg/d or furosemide 40 mg/d). We recruited 4,124 patients with a mean age of 69 (range 65–72) at study entry; 46% were women. Mean duration±standard error of follow-up with antihypertensive drugs was 8±1 years. One hundred five (2.5%) of the 4,124 patients were diagnosed with dementia, including vascular and degenerative. In those demented patients, we could identify 90 patients with AD according to the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association diagnostic criteria.6 In the analysis of individual groups of antihypertensive drugs, the incidence of AD was similar in subjects assigned to total ACE inhibitors (2.1%), calcium-channel blockers (2.1%), beta-blockers (2.6%), and diuretics (2.6%), but in the subgroup analysis of ACE inhibitors, the use of ACE inhibitors that can inhibit brain ACE was associated with a significantly lower incidence of AD than the use of those that cannot inhibit brain ACE (odds ratio=0.25, 95% confidence interval=0.08–0.75; P=.014) or the other types of drugs (Table 1). Use of lipid-lowering agents was comparable across different treatment groups. Long-term use of some specific ACE inhibitors may have a protective role against the development of AD, probably through their direct effects on RAS in the brain. Physicians should consider specific tissue distribution of ACE inhibitors with the hope of correlating these with actions in vivo that might be of clinical significance.
No takes yet. Share an insight, caveat, or question.
Ohrui et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: